All Updates

All Updates

icon
Filter
FDA approval
Signet Therapeutics receives IND approval from FDA for gastric cancer treatment
AI Drug Discovery
Jul 1, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jul 1, 2024

Signet Therapeutics receives IND approval from FDA for gastric cancer treatment

FDA approval

  • AI-based oncology therapy developer Signet Therapeutics has received FDA approval for its IND application for sigx1094, a targeted drug for diffuse gastric cancer (DGC). Following the approval, the company is prepared to commence Phase I clinical trials to assess the treatment's safety and efficacy against DGC and other advanced solid tumors.

  • Sigx1094 was developed using Signet's proprietary organoid disease model platform and AI in collaboration with AI-powered R&D platform company XtalPi. Organoids refer to 3D miniaturized versions of organs or tissues derived from stem cells. They can mimic an organ's key function, structure, and biological complexity, aiding in drug development and clinical trials. 

  • Signet Therapeutics focuses on developing targeted oncology therapeutics, leveraging advanced AI technology and disease models to enhance drug discovery and development processes. The company’s approach uses real-world cancer genomics data to create 3D organoid models, providing more clinically relevant data.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.